Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of ZY-19489 in Healthy Adults
NCT05206201Phase 1Completed
- Sponsor
- Zydus Lifesciences Limited
- Start
- Aug 2021
- Primary completion
- Jan 2022
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ZY19489 in malaria (4 arms), sponsored by Zydus Lifesciences Limited. Primary endpoint: Incidence and Severity of Adverse event of ZY-19489. Started Aug 2021; status: completed.
02
Drugs
ZY19489
03
Conditions
malaria
Beyond the preview
Go deeper on NCT05206201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05206201.